Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12578570 | 1.00 | GLA (0.42) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL13579581 | 1.00 | GLA (0.42) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL1896218 | 1.00 | GLA (0.42) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL1844624 | 1.00 | GLA (0.42) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL1844620 | 1.00 | GLA (0.42) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL1844621 | 1.00 | GLA (0.42) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL706736 | 0.98 | HSD11B1 (0.41) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| Methyl Alcohol SCHEMBL5319479 | 0.98 | HSD11B1 (0.41) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| Methyl Alcohol SCHEMBL5318301 | 0.97 | HSD11B1 (0.40) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL15831171 | 0.89 | GLA (0.47) | GLAHSD11B1SCN9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929675-B | Adamantane derivatives as focal adhesion kinase inhibitors | 三进制药株式会社 | 2024-02-13 | — | — | CN | disclosed |
| US-20230049557-A1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | INCHEON NATIONAL UNIVERSITY RESEARCH & BUSINESS FOUNDATION (KR) | 2023-02-16 | — | — | US | disclosed |
| EP-4074697-A2 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | Samjin Pharmaceutical Co., Ltd. (KR) | 2022-10-19 | — | — | EP | disclosed |
| CN-114929675-A | Novel adamantane derivatives as inhibitors of focal adhesion kinase | 三进制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021111311-A2 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | 삼진제약주식회사 | 2021-06-10 | — | — | WO | disclosed |
| WO-2021111311-A2 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | 삼진제약주식회사 | 2021-06-10 | — | — | WO | disclosed |
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-2865664-B1 | NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | BAMICHEM CO LTD (KR) | 2017-11-01 | — | — | EP | disclosed |
| WO-2017153235-A1 | SUBSTITUTED N-CYCLO-3-ARYL-1-NAPHTHAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-14 | — | — | WO | disclosed |
| US-9464044-B2 | Compound having ability to inhibit 11Beta-HSD1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | AHN-GOOK PHARMACEUTICAL CO., LTD. (KR) | 2016-10-11 | — | — | US | disclosed |
| EP-1846363-A2 | ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | MADAR DAVID J | 2007-10-11 | — | — | US | disclosed |
| US-20070179186-A1 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | ABBVIE INC. | 2007-08-02 | — | — | US | disclosed |
| US-7238724-B2 | Antidiabetic agents; hyperlipemic agents; obestity; immunomoderator; atherosclerosis | ABBOTT LABORATORIES (US) | 2007-07-03 | — | — | US | disclosed |
| US-7217838-B2 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid; fortherapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBOTT LABORATORIES (US) | 2007-05-15 | — | — | US | disclosed |
| US-20060281773-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006074244-A2 | ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148871-A1 | Metabolic stabilization of substituted adamantane | ABBOTT LABORATORIES | 2006-07-06 | — | — | US | disclosed |
| US-20060149070-A1 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid, for therapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBVIE INC. | 2006-07-06 | — | — | US | disclosed |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179186-A1 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | HSD17B1, HSD3B1, HSD17B2 | GLA 1807/4885HSD11B1 6/4885SCN9A 2515/4885 |
| US-20060149070-A1 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid, for therapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | HSD17B1, HSD11B1, HSD3B1 | GLA 1525/4885HSD11B1 2/4885SCN9A 2612/4885 |
| US-20060281773-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | GLA 1267/4885HSD11B1 1/4885SCN9A 2388/4885 |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | GLA 841/4885HSD11B1 544/4885SCN9A 2863/4885 |
| US-20230049557-A1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | PTK2, DAPK2, DAPK1 | GLA 3283/4885HSD11B1 3564/4885SCN9A 718/4885 |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | GLA 841/4885HSD11B1 544/4885SCN9A 2863/4885 |
| US-20060148871-A1 | Metabolic stabilization of substituted adamantane | HSD11B1, HSD17B1, HSD11B2 | GLA 996/4885HSD11B1 1/4885SCN9A 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.